Physician Photo

Elizabeth M. Vancott, MD

Associate Pathologist, Massachusetts General Hospital

Medical Director, Coagulation Service

Associate Professor of Pathology, Harvard Medical School

Dr. Van Cott is an expert coagulation pathology specialist. Her continuous contributions to the advancement of laboratory guidelines and standards are recognized by the CAP, NASCOLA, CLSI, and THSNA organizations.

Department of Pathology


  • MassGeneral Hospital for Children
  • Stroke Services
  • Hemophilia and Thrombosis
Clinical Interests
Hemoglobin Electrophoresis
Boston: Massachusetts General Hospital
Medical Education
MD, Harvard Medical School
Residency, Massachusetts General Hospital
Board Certifications
Clinical Pathology, American Board of Pathology
Patient Age Group
Adult and pediatric
Accepting New Patients
Accepting New Patients


Elizabeth Van Cott, MD is Director of the Coagulation Laboratory, and Medical Director of the Core Laboratory at Massachusetts General Hospital. She is past president of the North American Specialized Coagulation Laboratory Association (NASCOLA), and is chair of the Proficiency Testing/External Quality Assessment program. She is an advisor for the Area Committee on Hematology for the Clinical and Laboratory Standards Institute (CLSI), and contributes to writing coagulation laboratory guidelines for CLSI. Dr. Van Cott is an inaugural member of the Standards Committee of the College of American Pathologists (CAP), and was a committee member of the Coagulation Resource Committee for six years. She is an inaugural director on the board of the Thrombosis and Hemostasis Societies of North America (THSNA) and is still a director. Dr. Van Cott was an invited expert at two recent CAP consensus conferences on coagulation, which generated national consensus guidelines for laboratory monitoring of anticoagulant therapy, and thrombophilia. She has over 100 publications on coagulation, and is an editor or editorial board member of multiple journals.


Research interests include:

  • Clinically-oriented studies in thrombosis and hemostasis

  • Research is focused on coagulation, in particular, diagnostic coagulation testing and heparin-induced thrombocytopenia (HIT), including new anticoagulants for the treatment of HIT


View my most recent publications at PubMed

  1. The effects of dabigatran on lupus anticoagulant, diluted plasma thrombin time, and other specialized coagulation assays. Kim YA, Gosselin R, Van Cott EM. Int J Lab Hematol. 2014 Dec 17. doi: 10.1111/ijlh.12319. [Epub ahead of print] No abstract available.
  2. Activated protein C resistance testing for factor V Leiden. Kadauke S, Khor B, Van Cott EM.Am J Hematol. 2014 Dec;89(12):1147-50.
  3. Increased transfusion-free survival following auxiliary pig liver xenotransplantation. Yeh H, Machaidze Z, Wamala I, Fraser JW, Navarro-Alvarez N, Kim K, Schuetz C, Shi S, Zhu A, Hertl M, Elias N, Farkash EA, Vagefi PA, Varma M, Smith RN, Robson SC, Van Cott EM, Sachs DH, Markmann JF. Xenotransplantation. 2014 Sep-Oct;21(5):454-64. doi: 10.1111/xen.12111. Epub 2014 Aug 1.

Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-726-9468
Fax: 617-726-3256